Back to search

Article

Oligoclonal B cell Expansion and Passenger Fusion Genes Predict Response to Nivolumab in Recurrent Ovarian Cancer: Phase II Kyoto Trial

2025-09-11

Abstract excerpt

<title>Abstract</title> <p> <italic> <bold>Background</bold> </italic> <bold>:</bold> We previously reported a phase II Kyoto trial for platinum-resistant ovarian cancer (n = 20) using nivolumab (anti-programmed cell death-1 [PD-1] antibody). We evaluated the associations between clinical outcomes and transcriptomics and T and B cell clonality from tumor and blood cells. <italic> <bold>Methods</bold> </it...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fe918311-415a-58a1-b988-dd063ced7b94
DOI
10.21203/rs.3.rs-7492478/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oligoclonal B cell Expansion and Passenger Fusion Genes Predict Response to Nivolumab in Recurrent Ovarian Cancer: Phase II Kyoto TrialDOI 10.21203/rs.3.rs-7492478/v1
The mutational load and a T-cell inflamed tumor phenotype identify ovarian cancer patients rendering tumor-reactive T cells from PD-1+ tumor-infiltrating lymphocytesSemantic proximity
Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trialSemantic proximity
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.Semantic proximity
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity
Single-Cell Analysis Reveals Ide-cel and Cilta-cel Characteristics That Influence EfficacySemantic proximity
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterSemantic proximity
Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.Semantic proximity
Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancerSemantic proximity
Alterations in Intratumoral Immune Response Before and Early-on-Treatment of Nivolumab in Unresectable Advanced or Recurrent Gastric CancerSemantic proximity
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in Arm A of the NSGO-OV-UMB1/ENGOT-OV30 trialSemantic proximity
Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal Region B cell lymphomaSemantic proximity
Select a neighboring publication to make it the new centre.